Drug · DIN 02237484
CELLCEPT
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since November 11, 1998; first marketed November 11, 1998.
- Drug Identification Number (DIN)
- 02237484
- Company (DIN owner)
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Mycophenolic acid L04AA06
- Class
- Human
- Record last updated
- June 25, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| MYCOPHENOLATE MOFETIL | 500 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 5, 1998: NOC 3061Supplement to a New Drug Submission (SNDS) · New strength and dosage form
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “cellcept”. A notice may cover another product or only some lots: read it to see what it covers.
- CellCept (mycophenolate mofetil) and MYFORTIC (mycophenolate sodium) - Serious Risk of Teratogenicity in Mycophenolate-Containing ProductsJanuary 18, 2016 · Drugs · Product safety
- Archived - Association of CellCept (mycophenolate mofetil) with a potential risk of pure red cell aplasia (PRCA) - For the PublicJune 4, 2009 · Drugs
- Association of CellCept (mycophenolate mofetil) with a potential risk of pure red cell aplasia (PRCA) - For Health ProfessionalsJune 4, 2009 · Drugs
- Archived - Association of CellCept (mycophenolate mofetil) and sirolimus containing immunosuppressant regimen with higher rate of acute rejection in cardiac transplant patients switched from calcineurin inhibitorsOctober 25, 2006 · Drugs
- Archived - CellCept (mycophenolate mofetil) - Advisories, Warnings and Recalls for the PublicOctober 25, 2006 · Drugs
Other DINs named CELLCEPT
- DIN 02192748 · Marketed
- DIN 02242145 · Marketed